Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IL23R | Q5VWK5 | 3/20 | 0.62 |
| ▸ | CXCR4 | P61073 | 9/20 | 0.62 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.57 |
| ▸ | CALCA | P06881 | 2/20 | 0.57 |
| ▸ | NPY1R | P25929 | 1/20 | 0.54 |
| ▸ | NPY2R | P49146 | 1/20 | 0.54 |
| ▸ | NPY4R | P50391 | 1/20 | 0.54 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.54 |
| ▸ | RAMP3 | O60896 | 3/20 | 0.53 |
| ▸ | CALCR | P30988 | 3/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31433346 | 0.94 | CXCR4 (0.59) | IL23RCXCR4C5AR1 | |
| SCHEMBL31433347 | 0.91 | KISS1R (0.56) | IL23RCXCR4C5AR1 | |
| SCHEMBL29436331 | 0.90 | IL23R (0.70) | IL23RCXCR4C5AR1NPY1RNPY2R | |
| SCHEMBL31433253 | 0.90 | CXCR4 (0.61) | IL23RCXCR4C5AR1CALCA | |
| SCHEMBL31433232 | 0.90 | CXCR4 (0.58) | IL23RCXCR4C5AR1 | |
| SCHEMBL31433330 | 0.90 | CXCR4 (0.64) | IL23RCXCR4C5AR1CALCANPY1R | |
| SCHEMBL31433169 | 0.90 | IL23R (0.66) | IL23R | |
| SCHEMBL31433250 | 0.89 | CTSL (0.60) | IL23RCXCR4C5AR1 | |
| SCHEMBL31433316 | 0.89 | CAPN1 (0.61) | IL23RCXCR4CALCA | |
| SCHEMBL31433337 | 0.89 | RAMP3 (0.55) | IL23RCXCR4RAMP3CALCR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250074942-A1 | COMPOSITIONS AND METHODS FOR COVALENT PEPTIDE-BASED MODULATORS OF HLA-E | CALICO LIFE SCIENCES LLC (US) | 2025-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250074942-A1 | COMPOSITIONS AND METHODS FOR COVALENT PEPTIDE-BASED MODULATORS OF HLA-E | MICA, CD74, HLA-DRB1 | IL23R 710/4885CXCR4 429/4885C5AR1 1505/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.